Haymaker Acquisition Corp. 4

# Signal Note: Driehaus Capital Position in Haymaker Acquisition 4 Driehaus Capital's $387K warrant position in HYAC suggests conviction in an upcoming SPAC merger; Haymaker 4's target remains undisclosed, but the firm's biotech focus indicates interest in a clinical or commercial-stage asset. Warrant positioning provides leveraged exposure to merger announcement catalysts and potential clinical data readouts, though execution risk is elevated given typical SPAC timelines and regulatory uncertainty.